Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 29, 2025
Daily News
September 29, 2025
- Industry Fears Trump’s MFN Drug Pricing Push Could Deepen Japan’s Lag and Loss
September 29, 2025
- Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
- Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
- US Confirms 50% Tariffs on Japan’s Heavy Trucks; Pharma Capped at 15%
September 29, 2025
- Japan to Set Criteria for “Challenge Applications” in Medical Device Pricing Reform
September 29, 2025
- Riken Genesis CDx Earns Japan Nod for Truqap Combo Therapy
September 29, 2025
- Meiji Rolls Out 2-Dose Vial of COVID-19 Vaccine Kostaive
September 29, 2025
- Japan Says It’s Too Early to Gauge Impact of US Pharma Tariffs
September 29, 2025
- Generic Use Rate Hits Record 89.2% in April-June: JGA
September 29, 2025
- The Keen Eye: Awareness as a Leadership Cornerstone
September 29, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…